Maven Securities’s Avita Medical RCEL Stock Holding History

Maven Securities’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-53,283	Closed	-$1.04M	–	1281
2021 Q1	$1.04M	Buy	+53,283	New	+$1.24M	0.05%	392

Other funds holding RCEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Blackcrane Capital Bellevue, Washington $16.3M AUM 19.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Maven Securities's RCEL Position: Q2 2021 in Review

Maven Securities sold out of Avita Medical (RCEL) in Q2 2021, closing a stake of 53,283 shares — an estimated $1.04M sold.

Maven Securities first reported a position in RCEL in Q1 2021 and held it in 1 quarter. The position peaked at $1.04M in Q1 2021. 71 funds tracked by Wall St. Rank hold RCEL as of Q2 2021.

Maven Securities reported no remaining Avita Medical position as of Q2 2021 after selling out during the quarter.
Maven Securities sold 53,283 Avita Medical shares in Q2 2021, an estimated $1.04M.
Maven Securities first reported a position in Avita Medical in Q1 2021 and held it in 1 quarter.
Maven Securities's Avita Medical position peaked at $1.04M in Q1 2021.
71 funds tracked by Wall St. Rank held Avita Medical as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.